Clinical development of MET targeted therapy for human cancer

Nima Tirgan, Zhe Tang, Patrick Chi-Chung Ma

Research output: Contribution to journalReview article

3 Citations (Scopus)

Abstract

MET is a member of the semaphorins, plexins and MET/RON receptor family, which is stimulated by the ligand hepatocyte growth factor (HGF) and uniquely regulates a wide range of cellular functions. When dysregulated and activated, as in the case of human cancers with MET amplification or overexpression, mutation or alternative splicing, it has been implicated to play pivotal role in human tumor cell progression and metastasis. MET-HGF signal path has been shown to be attractive therapeutic target for human cancer novel therapy. In recent years, substantial progresses have been achieved to advance MET-HGF inhibitory strategies from the bench-top preclinical studies to clinical trial studies. Targeting agents being developed include not only various small molecule MET inhibitors, but also specific anti-MET or anti-HGF antibodies. Current emerging knowledge of the kinases signaling cross-talk networks will eventually facilitate rational design of optimal treatment strategies combining MET inhibition with other inhibitors, such as erlotinib (against EGFR). In this review, we summarize the relevant MET receptor biology, mutations (especially non-kinase domain mutations) and other genomic alterations in human cancers. The strategies to inhibit MET-HGF as novel therapy in human cancer as well as agents undergoing clinical trial studies would be discussed. Finally, we also summarize the various challenges to be met, including predictive biomarkers identification, patient selection, and rational combinational treatment approaches.

Original languageEnglish (US)
Pages (from-to)261-270
Number of pages10
JournalCurrent Cancer Therapy Reviews
Volume5
Issue number4
DOIs
StatePublished - Dec 17 2009

Fingerprint

Hepatocyte Growth Factor
Neoplasms
Mutation
Clinical Trials
Semaphorins
Therapeutics
Alternative Splicing
Patient Selection
Phosphotransferases
Biomarkers
Neoplasm Metastasis
Ligands
Antibodies

All Science Journal Classification (ASJC) codes

  • Molecular Medicine
  • Oncology
  • Cancer Research

Cite this

@article{a01ce5f149f24e03956d9a7e8c59835d,
title = "Clinical development of MET targeted therapy for human cancer",
abstract = "MET is a member of the semaphorins, plexins and MET/RON receptor family, which is stimulated by the ligand hepatocyte growth factor (HGF) and uniquely regulates a wide range of cellular functions. When dysregulated and activated, as in the case of human cancers with MET amplification or overexpression, mutation or alternative splicing, it has been implicated to play pivotal role in human tumor cell progression and metastasis. MET-HGF signal path has been shown to be attractive therapeutic target for human cancer novel therapy. In recent years, substantial progresses have been achieved to advance MET-HGF inhibitory strategies from the bench-top preclinical studies to clinical trial studies. Targeting agents being developed include not only various small molecule MET inhibitors, but also specific anti-MET or anti-HGF antibodies. Current emerging knowledge of the kinases signaling cross-talk networks will eventually facilitate rational design of optimal treatment strategies combining MET inhibition with other inhibitors, such as erlotinib (against EGFR). In this review, we summarize the relevant MET receptor biology, mutations (especially non-kinase domain mutations) and other genomic alterations in human cancers. The strategies to inhibit MET-HGF as novel therapy in human cancer as well as agents undergoing clinical trial studies would be discussed. Finally, we also summarize the various challenges to be met, including predictive biomarkers identification, patient selection, and rational combinational treatment approaches.",
author = "Nima Tirgan and Zhe Tang and Ma, {Patrick Chi-Chung}",
year = "2009",
month = "12",
day = "17",
doi = "10.2174/157339409789712708",
language = "English (US)",
volume = "5",
pages = "261--270",
journal = "Current Cancer Therapy Reviews",
issn = "1573-3947",
publisher = "Bentham Science Publishers B.V.",
number = "4",

}

Clinical development of MET targeted therapy for human cancer. / Tirgan, Nima; Tang, Zhe; Ma, Patrick Chi-Chung.

In: Current Cancer Therapy Reviews, Vol. 5, No. 4, 17.12.2009, p. 261-270.

Research output: Contribution to journalReview article

TY - JOUR

T1 - Clinical development of MET targeted therapy for human cancer

AU - Tirgan, Nima

AU - Tang, Zhe

AU - Ma, Patrick Chi-Chung

PY - 2009/12/17

Y1 - 2009/12/17

N2 - MET is a member of the semaphorins, plexins and MET/RON receptor family, which is stimulated by the ligand hepatocyte growth factor (HGF) and uniquely regulates a wide range of cellular functions. When dysregulated and activated, as in the case of human cancers with MET amplification or overexpression, mutation or alternative splicing, it has been implicated to play pivotal role in human tumor cell progression and metastasis. MET-HGF signal path has been shown to be attractive therapeutic target for human cancer novel therapy. In recent years, substantial progresses have been achieved to advance MET-HGF inhibitory strategies from the bench-top preclinical studies to clinical trial studies. Targeting agents being developed include not only various small molecule MET inhibitors, but also specific anti-MET or anti-HGF antibodies. Current emerging knowledge of the kinases signaling cross-talk networks will eventually facilitate rational design of optimal treatment strategies combining MET inhibition with other inhibitors, such as erlotinib (against EGFR). In this review, we summarize the relevant MET receptor biology, mutations (especially non-kinase domain mutations) and other genomic alterations in human cancers. The strategies to inhibit MET-HGF as novel therapy in human cancer as well as agents undergoing clinical trial studies would be discussed. Finally, we also summarize the various challenges to be met, including predictive biomarkers identification, patient selection, and rational combinational treatment approaches.

AB - MET is a member of the semaphorins, plexins and MET/RON receptor family, which is stimulated by the ligand hepatocyte growth factor (HGF) and uniquely regulates a wide range of cellular functions. When dysregulated and activated, as in the case of human cancers with MET amplification or overexpression, mutation or alternative splicing, it has been implicated to play pivotal role in human tumor cell progression and metastasis. MET-HGF signal path has been shown to be attractive therapeutic target for human cancer novel therapy. In recent years, substantial progresses have been achieved to advance MET-HGF inhibitory strategies from the bench-top preclinical studies to clinical trial studies. Targeting agents being developed include not only various small molecule MET inhibitors, but also specific anti-MET or anti-HGF antibodies. Current emerging knowledge of the kinases signaling cross-talk networks will eventually facilitate rational design of optimal treatment strategies combining MET inhibition with other inhibitors, such as erlotinib (against EGFR). In this review, we summarize the relevant MET receptor biology, mutations (especially non-kinase domain mutations) and other genomic alterations in human cancers. The strategies to inhibit MET-HGF as novel therapy in human cancer as well as agents undergoing clinical trial studies would be discussed. Finally, we also summarize the various challenges to be met, including predictive biomarkers identification, patient selection, and rational combinational treatment approaches.

UR - http://www.scopus.com/inward/record.url?scp=71849102183&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=71849102183&partnerID=8YFLogxK

U2 - 10.2174/157339409789712708

DO - 10.2174/157339409789712708

M3 - Review article

AN - SCOPUS:71849102183

VL - 5

SP - 261

EP - 270

JO - Current Cancer Therapy Reviews

JF - Current Cancer Therapy Reviews

SN - 1573-3947

IS - 4

ER -